Abstract:
α-blocker is a classic antihypertensive drug class and indispensable in the management of hypertension. This Chinese experts consensus document is the first that summarizes evidence and provides recommendations on the efficacy and safety of α-blockers in the treatment of refractory hypertension, hypertension with comorbid benign prostatic hyperplasia, dyslipidemia and hyperglycemia, and chronic kidney disease, hypertensive emergency, pheochromocytoma and primary aldosteronism under screening. It also attempts to provide guidance for the optimized use of α-blockers in the management of hypertension.